SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics Inc. has entered into a licensing agreement with Denmark’s Adcendo ApS, a specialist in antibody drug conjugates (ADCs). The deal grants Adcendo exclusive global rights to develop and commercialize an anti-human tissue factor (TF) ADC, ADCE-T02, with the exception of Greater China, where Multitude retains all rights.
The ADCE-T02 candidate, which leverages Multitude’s innovative T1000 exatecan linker payload technology, is poised to enhance the bystander effect, improve linker stability, and potentially overcome drug resistance mechanisms. This technology has demonstrated its ability to amplify the therapeutic efficacy of ADCs, a key factor in the agreement’s significant value.
Adcendo is set to pay Multitude an upfront fee in the tens of millions of US dollars, with the potential for milestone payments reaching up to USD 1 billion, plus royalties on future sales. The agreement comes on the heels of ADCE-T02’s preparation for clinical trial filings in Australia and plans for a US filing in the near term, with the Phase I study in Australia expected to commence by Q4 2024.
This partnership is a testament to the growing global interest in ADCs and their role in transforming cancer treatment. It also underscores the strategic importance of partnerships in advancing cutting-edge therapies and bringing them to market.- Flcube.com
